Bastiano Sanna, EVP, Cell & Genetic Therapies at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 1,088 shares at $310.10 ($340K) on 2022-11-02, disclosed to the SEC on 2022-11-03.
Scheduled sale ($340k) by EVP, Cell & Genetic Therapies under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $312.84 | 768 | $240K | 70.6% |
| 2 | $310.10 | 56 | $17K | 5.1% |
| 3 | $311.17 | 39 | $12K | 3.6% |
| 4 | $312.40 | 100 | $31K | 9.2% |
| 5 | $313.37 | 81 | $25K | 7.5% |
| 6 | $314.43 | 12 |
| $4K |
| 1.1% |
| 7 | $315.68 | 10 | $3K | 0.9% |
| 8 | $317.77 | 22 | $7K | 2.1% |
| Total | $312.78 avg | 1,088 | $340K | 100% |
| Filing → |
| VRTX | SELL | 2023-04-14 | $4.9M | — | Filing → |
| VRTX | SELL | 2023-04-06 | $231K | — | Filing → |
| VRTX | SELL | 2023-03-20 | $1.7M | — | Filing → |